This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Phase 3 Trial Comparing Vectibix® (Panitumumab) To Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival

THOUSAND OAKS, Calif., Sept. 28, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix ® (panitumumab) to Erbitux ® (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy. The study met its primary endpoint, demonstrating that panitumumab was non-inferior to cetuximab for overall survival. The results were presented in an oral presentation at the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress in Amsterdam (Abstract No. 18).

The prospective study showed that the median overall survival for patients treated with panitumumab was 10.4 months (range 9.4 months to 11.6 months) compared to 10 months (range 9.3 months to 11.0 months) for patients treated with cetuximab (95 percent CI, 0.84-1.11, p=0.0007).

Colorectal cancer is the second leading cause of cancer deaths. 1,2 Approximately 1.2 million cases of colorectal cancer are expected to occur globally.

"ASPECCT was a well-conducted and robust Phase 3 trial involving nearly 1,000 patients globally with metastatic colorectal cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Colorectal cancer is a devastating disease and these results provide physicians with important new information about the role Vectibix can play as they evaluate treatment options."

In the study, progression-free survival was a median of 4.1 months in patients treated with panitumumab versus 4.4 months in patients treated with cetuximab (HR=1.00, 95 percent CI, 0.88, 1.14). Objective response rate, which is the percentage of patients who experienced tumor size reduction, was 22 percent for patients treated with panitumumab compared to 19.8 percent for patients in the cetuximab arm (Odds Ratio 1.15, 95 percent CI, 0.83, 1.58).

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.93 1.40%
FB $117.87 -0.59%
GOOG $694.35 -0.55%
TSLA $234.71 -2.90%
YHOO $36.03 -1.40%


Chart of I:DJI
DOW 17,729.16 -162.00 -0.91%
S&P 500 2,059.31 -22.12 -1.06%
NASDAQ 4,760.8110 -56.7830 -1.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs